9-Jun-2023
Creso Pharma and Apotheke Dr. Hysek partner to import MDMA and psilocybin treatments to Australia
5-Jun-2023
Creso Pharma trains sights on lucrative Australian market following change in licensing process
22-May-2023
Creso Pharma reports strong sales, licence extensions for Canadian subsidiary Mernova
19-May-2023
Creso Pharma raises A$2.5 million, streamlines balance sheet for growth strategy
17-May-2023
Creso Pharma strengthens market position on completing Health House International acquisition
15-May-2023
Creso Pharma hones in on pivotal Asian markets with Singapore and South Korea distribution deals
10-May-2023
Creso Pharma has eyes on multi-million dollar functional mushroom product market
8-May-2023
Creso Pharma gains Supreme Court green light for Health House acquisition
5-May-2023
Creso Pharma's subsidiary Halucenex demonstrates potential of psilocybin to treat PTSD
1-May-2023
Creso Pharma subsidiary secures new purchase orders and expands into Alberta
1-May-2023
Creso Pharma has strong foundation for growth across multiple verticals
6-Mar-2023
Creso Pharma boosts balance sheet through A$2.5 million convertible note issue
17-Feb-2023
Creso Pharma boosts finances for marketing push into US, psilocybin trial, with $2 million placement
9-Feb-2023
Creso Pharma has strong foundation for growth across multiple verticals in 2023
6-Feb-2023
Creso Pharma looks to bring psilocybin to Australian market after TGA downgrade
29-Jan-2023
Creso Pharma looks to acquire baby product company Abby and Finn; to streamline finance structure
23-Jan-2023
Creso Pharma expands Canadian footprint; secures largest purchase order ever
11-Jan-2023
Creso Pharma subsidiary Mernova to launch seven new products in Canada
9-Jan-2023
Creso Pharma draws additional A$500,000 on funding facility; shareholders approve A$2 million in placement participation by directors
7-Dec-2022
Creso Pharma subsidiary Halucenex doses first patient in Lucenex Phase 2 trial targeting PTSD
30-Nov-2022
Creso Pharma taps Peter Hatfull for board seat
23-Nov-2022
Creso Pharma starts to unlock Health House revenue streams and expansion initiatives
22-Nov-2022
Creso Pharma welcomes news it is “no longer the subject of investigation” by ASIC
21-Nov-2022
Creso Pharma inks scheme implementation deed to acquire Health House International
18-Nov-2022
Creso Pharma welcomes Canadian subsidiary’s large purchase orders from Saskatchewan cannabis co-operative
9-Nov-2022
Creso Pharma US subsidiary Sierra Sage Herbs expands Green Goo into Canada
3-Nov-2022
Creso Pharma’s Mernova awarded amended Health Canada sales licence
1-Nov-2022
Creso Pharma to raise $7.6 million through an issue of two separate convertible notes
19-Oct-2022
Creso Pharma to rebrand as Melodiol Global Health to better represent its international ambitions
13-Oct-2022
Creso Pharma US subsidiary Sierra Sage Herbs LLC inks wholesale agreement with accelerate360
10-Oct-2022
Creso Pharma accelerates growth strategy with director appointments, board transition and rebranding
6-Oct-2022
Creso Pharma to start psilocybin clinical trials into PTSD via wholly-owned Halucenex
4-Oct-2022
Creso Pharma subsidiary Mernova expands Canadian medicinal cannabis footprint
29-Sep-2022
Creso Pharma subsidiary Mernova Medicinal broadens Canadian footprint with provincial partnerships
14-Sep-2022
Creso Pharma psychedelics subsidiary Halucenex kicks off Phase 2 of psilocybin PTSD clinical trial
5-Sep-2022
Creso Pharma advances Health House International transaction
2-Sep-2022
Creso Pharma subsidiary secures US$214,000 purchase order from Walmart
29-Aug-2022
Creso Pharma launches into US CBD market on completing Sierra Sage Herbs acquisition
22-Aug-2022
Creso Pharma subsidiary Halucenex poised to begin psilocybin PTSD clinical trial following Health Canada update
15-Aug-2022
Creso Pharma subsidiary appoints renowned sports performance coach as brand ambassador ahead of product launch
8-Aug-2022
Creso Pharma’s Canadian subsidiary generates revenue of $3 million year-to-date
4-Aug-2022
Creso Pharma raising A$7 million for further US expansion
31-Jul-2022
Creso Pharma inks non-binding term sheet to acquire international pharmaceutical distributor Health House
25-Jul-2022
Creso Pharma target Sierra Sage Herbs secures private label manufacturing agreement with US online retailer
21-Jul-2022
Creso Pharma subsidiary Mernova delivers new Ontario cannabis sales
18-Jul-2022
Creso Pharma psychedelics subsidiary Halucenex Life Sciences broadens scope ahead of Phase 2 clinical trials
14-Jul-2022
Creso Pharma's Canadian subsidiary ImpACTIVE appoints three new brand ambassadors ahead of launch
12-Jul-2022
Creso Pharma secures LOI to commercialise anibidiol® products targeting pet health in South Korea
7-Jul-2022
Creso Pharma inks agreement to launch Sierra Sage Herbs pet care products in Singapore
30-Jun-2022
Creso Pharma agreement sees it spread wings in Taiwan’s growing animal health market
28-Jun-2022
Creso Pharma’s Canadian subsidiary Mernova lands first purchase order for Ritual Gold vaporiser products
14-Jun-2022
Creso Pharma subsidiary receives first order for new strains and takes third place in Cannabis Cup
30-May-2022
Creso Pharma’s psychedelics company signs psilocybin supply agreement
23-May-2022
Creso Pharma eyes potential pathway into Australian body care market through Dr Pickles agreement, shares higher
10-May-2022
Creso Pharma’s psychedelics subsidiary Halucenex secures psilocybe cubensis import permit from Health Canada
7-Apr-2022
Creso Pharma acquisition target expands US footprint
4-Apr-2022
Creso Pharma welcomes passing of Cannabis Act in US House of Representatives
31-Mar-2022
Creso Pharma secures LOI for commercialisation with Laboratorios Brouwer to broaden LATAM market sales
28-Mar-2022
Creso Pharma hits major mushroom milestones
20-Mar-2022
Creso Pharma subsidiary Mernova achieves market milestone and improves crop yield
16-Mar-2022
Creso Pharma set to unlock US product sales and manufacturing with Sierra Sage Herbs
28-Feb-2022
Creso Pharma’s psychedelics company cleared to start clinical trials
25-Feb-2022
Creso Pharma secures commitments to raise $5 million, plans to grow US footprint
21-Feb-2022
Creso Pharma set to launch new range of vaporisers as it expands its footprint in North America
15-Feb-2022
Creso Pharma’s acquisition of Sierra Sage Herbs see multiple product launches on the horizon
11-Feb-2022
Creso Pharma to develop hemp-based lozenge product and expand international opportunities
8-Feb-2022
Creso Pharma subsidiary on official list to provide psilocybin to Canadian doctors
3-Feb-2022
Creso Pharma pushes into US CBD market with revenue-generating acquisition